Viking Therapeutics (NASDAQ:VKTX) COO Marianna Mancini Sells 57,661 Shares

by · The Cerbat Gem

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) COO Marianna Mancini sold 57,661 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $32.98, for a total value of $1,901,659.78. Following the transaction, the chief operating officer directly owned 409,190 shares of the company’s stock, valued at approximately $13,495,086.20. This trade represents a 12.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Marianna Mancini also recently made the following trade(s):

  • On Tuesday, October 28th, Marianna Mancini sold 6,185 shares of Viking Therapeutics stock. The shares were sold at an average price of $35.00, for a total value of $216,475.00.

Viking Therapeutics Stock Performance

NASDAQ:VKTX traded down $3.28 during trading hours on Monday, hitting $32.14. The company’s stock had a trading volume of 8,255,722 shares, compared to its average volume of 1,999,261. Viking Therapeutics, Inc. has a 52-week low of $18.92 and a 52-week high of $43.55. The business’s 50-day moving average is $36.43 and its two-hundred day moving average is $32.36. The company has a market capitalization of $3.63 billion, a PE ratio of -15.16 and a beta of 0.71.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last issued its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.14). The firm’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) EPS. As a group, analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Viking Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VKTX. Allworth Financial LP raised its stake in Viking Therapeutics by 58.4% in the 2nd quarter. Allworth Financial LP now owns 955 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 352 shares during the last quarter. Glass Jacobson Investment Advisors llc purchased a new stake in shares of Viking Therapeutics during the second quarter worth about $28,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Viking Therapeutics in the second quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new position in shares of Viking Therapeutics in the third quarter valued at approximately $30,000. Finally, GAMMA Investing LLC lifted its stake in shares of Viking Therapeutics by 71.0% during the fourth quarter. GAMMA Investing LLC now owns 1,195 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 496 shares during the period. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on VKTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 19th. Cantor Fitzgerald set a $105.00 price objective on Viking Therapeutics in a report on Thursday, October 23rd. BTIG Research reissued a “buy” rating and issued a $125.00 target price on shares of Viking Therapeutics in a report on Monday, September 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a research report on Monday, September 29th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Viking Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $87.14.

Check Out Our Latest Stock Report on VKTX

Viking Therapeutics Company Profile

(Get Free Report)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.

Featured Articles